Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BCG, now over 100 years old, remains the only licensed vaccine against Tuberculosis. It confers good protection against severe disease and meningitis but doesn’t protect against lung disease. MVA85A was the first vaccine of the new generation to enter into efficacy testing. It is currently being tested in The Gambia, Senegal and South Africa.

Q: How big a problem is TB today?

HM: TB remains one of the major causes of disease and death throughout the world today. Last year there were 9 million new cases throughout the world and 2 million deaths. In addition, the emergence of multi-drug resistant strains and extensively drug resistant strains of MTB have meant that really we are not very good at treating this disease anymore in those situations. We know that a third of the world's population are latently infected with TB, which means that they are at risk of reactivation of that latent infection if they become immunosuppressed for any reason.

Q: How are tuberculosis and HIV linked?

HM: The geographical overlap between the TB and the HIV epidemic has really had a devastating impact, particularly in sub-Saharan Africa. We know that people who are infected with HIV have a 10% annual risk of reactivating their latent infection, compared with people who are HIV negative who have a 10% lifetime risk. In addition we know that people who are HIV infected are significantly more likely to get new infection with TB. Furthermore we know that people who are infected with HIV who develop TB disease, that TB then causes a progression of their HIV disease so these two pathogens really do have a devastating synergy.

Q: How well does the vaccination protect against tuberculosis?

HM: Vaccination is the most effective and efficient way to control any infectious disease outbreak. BCG is the only available licensed vaccine against TB and has been around for over a hundred years now. BCG is routinely given throughout the developing world at birth and we know that when it's given at birth it is good at protecting against severe disease and TB meningitis in particular, in the first 10 years of life. But we know that BCG doesn't protect against lung disease which is where the burden of mortality and morbidity are. We also know that boosting with BCG (giving it repeated times) doesn't make any difference and doesn't make it any better.

Q: How is your research linked into this?

HM: My research program over the last 10 years has been to develop new TB vaccines and to test them in clinical trials. MVA85A, one of the vaccines we've developed here is now the most clinically advanced new TB vaccine in the world. MVA85A went into clinical trials in 2002 and since then we've conducted 19 clinical trials, first in the UK, then in the Gambia, South Africa, and more recently in Senegal, testing the safety primarily of this vaccine in different populations, in different ages, in TB infected patients and in HIV infected patients more recently. Last year MVA85A entered into a Phase IIb efficacy trial in South African babies and that study will run for the next 2 years when we'll actually find out for the first time whether this vaccine actually works to stop people getting TB disease. Next year we'll start a big study in HIV infected adults as they're also a really important target population for a new TB vaccine.

Q: How does your research fit into translational medicine within the department?

HM: One definition of translational medicine is taking things from the laboratory through into the clinic and that's exactly what we do in my program. MVA85A is a vaccine I made in my PhD and its now the most clinically advanced new TB vaccine being tested in several countries throughout the world.

Helen McShane

Development of a new vaccine against Tuberculosis

Professor Helen McShane has been working on a new TB vaccine for 10 years. There are about 9 million new cases and 1.7 million deaths every year from tuberculosis. She developed MVA85A, a vaccine with the aim to boost the cellular immune response induced by BCG. Developing countries are especially in need of a new vaccine since HIV and TB epidemics overlap and show a devastating synergy.

More podcasts related to Epidemics & Vaccines

Mike English: Health services that deliver for newborns

Global Health

Basic hospital care may be key to saving newborn lives. Professor Mike English outlines a multidisciplinary project engaging policy-makers and practitioners in Kenya. This project demonstrated poor coverage of Nairobi’s 4.25 million population if a sick newborn baby needs quality hospital care. Using novel research approaches the team also identified how severe shortages of nurses contribute to poor quality of care for patients and negatively affect nurses themselves.

Tran Hien: Infectious diseases in the tropics

Global Health

Although incidence of malaria has decreased in Vietnam, the burden of infectious diseases remains high and weighs heavily on the health care system. Clinical research aims to allow investments to go further: findings in the laboratory, tested in clinical trials and then applied to the community, help improve diagnosis and management.

Ronald Geskus: Sophisticated biostatistics for complex clinical research

Global Health

The role of biostatisticians in clinical research is to contribute to trial design, by calculating sample size for example, and to help draw correct conclusions from the data, discriminating important information from noise. They are instrumental in the translation of a practical problem into a statistical model, and the translation of the result into practice.

Rogier Van Doorn: Research at OUCRU Hanoi

Global Health

Antibiotics are widely used in Vietnam, leading to widespread antimicrobial resistance. Monitoring antibiotic use helps inform the government to change treatment guidelines and implement antibiotic stewardship programmes. This may also prevent the transmission of resistant bacteria outside the country.

Heiman Wertheim: Clinical research in low and middle-income countries

Global Health

Drug resistant infections are a global crisis and we cannot focus on our own country only. Clinical trials in low and middle income countries where the burden is highest, as well as work with local communities and engagement with policy makers help influence public health policies.

Guy Thwaites: Tuberculosis meningitis

Global Health

Tuberculosis meningitis affects a fractions of TB patients but causes high levels of mortality and morbidity. A recent trial at OUCRU showed that aspirin can greatly improve outcomes. Such trial is typical of the work done in our Vietnam units, where all the research is focussed on improving the outcome for patients directly.

Motiur Rahman: OUCRU laboratory management

Global Health

OUCRU laboratories provide support to the unit’s extensive clinical research programme, from level 2 laboratory to SAPO 4 laboratory for high-risk pathogens responsible for zoonotic infections. Early diagnosis and detection of antimicrobial resistance helps prescribe the right medicine in time, contributing to better patient management.

Raph Hamers: Developing collaborative clinical trials in Indonesia

Global Health

Indonesia is a very populous country with a huge burden of infectious diseases such as TB, malaria, HIV and CNS infections. Running clinical trials requires high levels of expertise, currently developed and strengthened by institutions such as IOCRL (Universities of Indonesia and Oxford Clinical Research laboratory). Better collaborations will also help great ideas make a bigger impact.

Jeremy Day: Central nervous system and HIV infections in Vietnam

Global Health

Brain infections such as meningitis and encephalitis are highly debilitating diseases, and an accurate diagnostic is essential to give patients the best treatment available. For cryptococcal meningitis, clinical trials focus on prevention, for an early diagnosis, and novel ways to use existing treatments or repurpose old drugs.

Abhilasha Karkey: Connecting research with communities in Nepal

Global Health

Antimicrobial resistance is a huge burden in Nepal, particularly in hospitals where many nosocomial infections are caused by resistant pathogens. With limited resources, little infection controls and proper guidelines in place, finding out the main risk factors helps reduce infection rates within a hospital and better target vaccination campaigns.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.